Logo image of EVAX

EVAXION A/S (EVAX) Stock Fundamental Analysis

NASDAQ:EVAX - Nasdaq - US29970R3030 - ADR - Currency: USD

2.9974  +0.07 (+2.3%)

Fundamental Rating

2

Overall EVAX gets a fundamental rating of 2 out of 10. We evaluated EVAX against 553 industry peers in the Biotechnology industry. EVAX may be in some trouble as it scores bad on both profitability and health. EVAX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EVAX has reported negative net income.
In the past year EVAX has reported a negative cash flow from operations.
In the past 5 years EVAX always reported negative net income.
In the past 5 years EVAX always reported negative operating cash flow.
EVAX Yearly Net Income VS EBIT VS OCF VS FCFEVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of EVAX (-84.65%) is worse than 71.79% of its industry peers.
Industry RankSector Rank
ROA -84.65%
ROE N/A
ROIC N/A
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVAX Yearly ROA, ROE, ROICEVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

EVAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVAX Yearly Profit, Operating, Gross MarginsEVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

3

2. Health

2.1 Basic Checks

EVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
EVAX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EVAX has been reduced compared to 5 years ago.
EVAX has a better debt/assets ratio than last year.
EVAX Yearly Shares OutstandingEVAX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EVAX Yearly Total Debt VS Total AssetsEVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

EVAX has an Altman-Z score of -3.78. This is a bad value and indicates that EVAX is not financially healthy and even has some risk of bankruptcy.
EVAX has a Altman-Z score of -3.78. This is comparable to the rest of the industry: EVAX outperforms 45.93% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.78
ROIC/WACCN/A
WACC5.37%
EVAX Yearly LT Debt VS Equity VS FCFEVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

EVAX has a Current Ratio of 2.01. This indicates that EVAX is financially healthy and has no problem in meeting its short term obligations.
EVAX has a Current ratio of 2.01. This is in the lower half of the industry: EVAX underperforms 75.95% of its industry peers.
A Quick Ratio of 2.01 indicates that EVAX has no problem at all paying its short term obligations.
With a Quick ratio value of 2.01, EVAX is not doing good in the industry: 74.14% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.01
Quick Ratio 2.01
EVAX Yearly Current Assets VS Current LiabilitesEVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 82.55% over the past year.
Looking at the last year, EVAX shows a very strong growth in Revenue. The Revenue has grown by 2555.65%.
EPS 1Y (TTM)82.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
Revenue 1Y (TTM)2555.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 15.24% on average over the next years. This is quite good.
EVAX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 61.85% yearly.
EPS Next Y20.4%
EPS Next 2Y15.55%
EPS Next 3Y26.37%
EPS Next 5Y15.24%
Revenue Next Year-100%
Revenue Next 2Y0.95%
Revenue Next 3Y59.75%
Revenue Next 5Y61.85%

3.3 Evolution

EVAX Yearly Revenue VS EstimatesEVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M
EVAX Yearly EPS VS EstimatesEVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2031 2032 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EVAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVAX Price Earnings VS Forward Price EarningsEVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVAX Per share dataEVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as EVAX's earnings are expected to grow with 26.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.55%
EPS Next 3Y26.37%

More info and screens

0

5. Dividend

5.1 Amount

EVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVAXION A/S

NASDAQ:EVAX (7/29/2025, 10:02:51 AM)

2.9974

+0.07 (+2.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-27 2025-05-27/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners2.18%
Inst Owner Change-3.9%
Ins Owners0.68%
Ins Owner ChangeN/A
Market Cap18.93M
Analysts82.5
Price Target38.76 (1193.12%)
Short Float %2.15%
Short Ratio0.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.94%
Min EPS beat(2)11.56%
Max EPS beat(2)86.32%
EPS beat(4)4
Avg EPS beat(4)80.18%
Min EPS beat(4)11.56%
Max EPS beat(4)152.99%
EPS beat(8)7
Avg EPS beat(8)40.41%
EPS beat(12)10
Avg EPS beat(12)32.21%
EPS beat(16)12
Avg EPS beat(16)23.88%
Revenue beat(2)1
Avg Revenue beat(2)42.12%
Min Revenue beat(2)-92.79%
Max Revenue beat(2)177.04%
Revenue beat(4)3
Avg Revenue beat(4)77.43%
Min Revenue beat(4)-92.79%
Max Revenue beat(4)190.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.06%
PT rev (3m)19.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)13.98%
EPS NY rev (3m)25.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-96.25%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.66
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.8
EYN/A
EPS(NY)-1.86
Fwd EYN/A
FCF(TTM)-2.05
FCFYN/A
OCF(TTM)-2.05
OCFYN/A
SpS0.53
BVpS-0.26
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.65%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.01
Quick Ratio 2.01
Altman-Z -3.78
F-Score5
WACC5.37%
ROIC/WACCN/A
Cap/Depr(3y)21.76%
Cap/Depr(5y)127.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
EPS Next Y20.4%
EPS Next 2Y15.55%
EPS Next 3Y26.37%
EPS Next 5Y15.24%
Revenue 1Y (TTM)2555.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y0.95%
Revenue Next 3Y59.75%
Revenue Next 5Y61.85%
EBIT growth 1Y33.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.86%
OCF growth 3YN/A
OCF growth 5YN/A